Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2006

View Archived Issues

Speedel retains rights to SPP-200

MorphoSys signs second PER.C6 license agreement

TolerRx raises funding to develop TRX-4

Alantos begins phase I study with ALS 2-0426

Polyfunctional CD8+ HIV-1-specific T-cell responses seen with Remune

TNX-355 activity described in vitro and in clinical trial

GS-9137/ritonavir can be administered with zidovudine and emtricitabine/tenofovir

BTA-798 begins phase Ib study

Novel agents for treating neurological disorders disclosed in recent patent literature

Preclinical findings support the application of talnetant for schizophrenia

Novel treatment options for metabolic disorders described in recent Merck and Dainippon patents

Novel antiinfective agents disclosed in recent patent literature

TAMs get attention as drug targets

Epix and Predix complete merger

Geron report on the anti-HIV activity of their telomerase activator TAT-0002

Sirion Therapeutics completes merger with Sytera

Antisoma updates AS-1404 development progress

Novel agents for thrombotic disorders disclosed in recent Astellas patent

Further findings for Viprovex in anthrax testing

Cesamet now available for CINV

MaxCyte and Medinet collaborate on immuno-cell therapy

Marqibo studied in phase II trial for relapsed and refractory ALL

Enrollment completed in European phase III trial for LidoPAIN SP

Tindamax submitted for bacterial vaginosis

NeuroSearch cleared to begin phase IIb obesity study of tesofensine

Approvable letter for Arxxant

MedImmune files IND for MT-103

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...